We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Endpoint Determination Study Protocol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03459482
Recruitment Status : Completed
First Posted : March 9, 2018
Last Update Posted : March 18, 2022
Information provided by (Responsible Party):

Brief Summary:
This study is designed to evaluate the most applicable endpoints for evaluation of the Biomerica InFoods® IBS product.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome Other: Food Elimination Diet Not Applicable

Detailed Description:

The objective of this Endpoint Determination Study is to address key elements regarding a proposed larger clinical study design:

  1. Comparing different potential primary outcome measures
  2. Demonstrating that an exclusionary diet as determined by elevated IgG levels using the Biomerica InFoods® IBS Test is associated with alleviation of IBS symptoms
  3. Demonstrating the ability to mask the sham diet
  4. Demonstrating the safety of the exclusionary diet

Subjects' diets will be based on the results of the Biomerica, InFoods® IBS Test.

Immunoglobulin G (IgG) levels above a certain threshold are considered a positive response against a specific food or foods. It is expected that severity of symptoms of IBS will decrease when foods that generate a positive immune response in the Biomerica InFoods® IBS test are eliminated from the diet of the IBS patient.

The Endpoint Determination Study format will be a double-blinded randomized controlled clinical study enrolling subjects at two trial sites within the United States and designed to evaluate the use of IgG antibody guided dietary restrictions, based on the Biomerica InFoods® IBS Test, in the management of patients diagnosed with Irritable Bowel Syndrome (IBS).

The 2 sites will enroll approximately equal numbers of subjects. The target for each site is a minimum of 30 subjects in each classification: IBS with diarrhea [IBS-D], IBS with constipation [IBS-C] and IBS mixed [IBS-M] for a minimum of 90 patients per site, 180 total subjects for this study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 556 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Design
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Endpoint Determination Study for An Antibody Guided Dietary Restriction Trial Using Biomerica InFoods® IBS Test in Patients With a Previous Diagnosis of Irritable Bowel Syndrome (IBS)
Actual Study Start Date : June 21, 2018
Actual Primary Completion Date : December 31, 2021
Actual Study Completion Date : December 31, 2021

Arm Intervention/treatment
Experimental: Group 1 - True Food Elimination Diet
Group 1 (experimental group): Subjects will be given an elimination diet based upon foods with a positive antibody profile in the Biomerica InFoods® IBS test. The elimination diet will also exclude any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
Other: Food Elimination Diet
Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Sham Comparator: Group 2 - Sham Food Elimination Diet
Group 2 (control group): Subjects will be given a "Sham" elimination diet. The sham diet will eliminate the same number of foods but none of the actual foods to which the patient had a positive antibody profile in the Biomerica InFoods® IBS test. The sham diet will also eliminate any and all foods to which the subject has a known IgE allergy and foods the subject already currently eliminates.
Other: Food Elimination Diet
Subjects asked to participate in a food elimination diet, either True or Sham to evaluate the effects on their IBS symptoms

Primary Outcome Measures :
  1. Change in the IBS-API - Abdominal Pain Intensity. The IBS-API is being assessed daily from enrollment (baseline) to study completion; total 10 weeks [ Time Frame: Daily for 10 weeks ]
    Abdominal pain intensity will be measured daily using an 11-point (0-10) numeric rating scale (NRS) that asks subjects to rate their worst abdominal pain over the past 24-hours.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 21 years old or older.
  • Able to read and understand English.
  • Have access to a computer and/or cell phone access for Electronic Data Capture (EDC)
  • Meets Rome III or Rome IV Diagnostic Criteria for IBS
  • Respond "No" to IBS Adequate Relief (IBS-AR) in the past week at the screening Visit#1.
  • Score between ≥ 3 and <7.5 on the Abdominal Pain Intensity Assessment (IBS_API) based on a weekly average of worst daily (in past 24 hours) abdominal pain on a 0 to 10 point scale.
  • A positive IgG antibody response for at least one food in the Biomerica InFoods® IBS panel
  • Patients who are on stable (> 3 months) doses of medications or treatments for their IBS (e.g., probiotics, fiber, Viberzi, Linzess, Amitiza, Alosetron, Plecanatide, anticholinergics, antidepressants, Zofran bile acid sequestrants, or anti-diarrheals) will be allowed to continue their medications as long as no change in treatment is planned for the duration of the study and no dose adjustment is made during the duration of the study.
  • Willing to follow a food elimination diet.

Exclusion Criteria:

  • Cannot use EDC system due to no cell phone and no computer access
  • Unable to provide consent.
  • Pregnant or breastfeeding
  • Does not qualify for a diagnosis of IBS by Rome III or IV Diagnostic Criteria
  • Diagnosed IBS, but an IBS-API score of <3.0 and >7.5
  • Patients who have used Rifaximin in the past 3 months
  • Patients engaged in another type of diet therapy i.e. FODMAP
  • Patients which physicians are anticipating starting a new medication, change in dosage, diet or other treatment for IBS during the study
  • Chronic pain from other conditions besides IBS
  • Current or previous use of narcotic medications within past 3 months
  • History of prior GI surgery except for cholecystectomy or appendectomy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03459482

Layout table for location information
United States, Arizona
Mayo Clinic
Scottsdale, Arizona, United States, 85259
United States, Florida
Mayo Clinic
Jacksonville, Florida, United States, 32224
United States, Illinois
Family Medicine Specialists
Wauconda, Illinois, United States, 60084
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, Michigan
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109-5362
United States, Texas
Houston Methodist Research Institute
Houston, Texas, United States, 77030
UT Health
Houston, Texas, United States, 77030
Gastroenterology Research of San Antonio
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: William D Chey, MD University of Michigan
Principal Investigator: Anthony J Lembo, MD Beth Israel Deaconess Medical Center (Harvard)
Layout table for additonal information
Responsible Party: Biomerica
ClinicalTrials.gov Identifier: NCT03459482    
Other Study ID Numbers: EPT-InF24-001
First Posted: March 9, 2018    Key Record Dates
Last Update Posted: March 18, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: It is not yet known if there will be a plan to make IPD available.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Pathologic Processes
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases